Merck Sharp + Dohme Corp.

Candido Gude

Timothy Allen Blizzard

Ravi P Nargund

Hubert B Josien

Qun Dang

Barbara A Pio

Purakkattle J Biju

Helen Y Chen

Harry R Chobanian

Tesfaye Biftu

William K Hagmann

Alexander Pasternak

Bin Hu

Dong Xiao

Steven L Colletti

Jinlong Jiang

Feroze Ujjainwalla

Ping Liu

Dooseop Kim

Haifeng Tang

Fa-Xiang Ding

Songnian Lin

John S Debenham

Shawn P Walsh

Cheng Zhu

Bowei Wang

Bing Li

Linus S Lin

Shuzhi Dong

De-Yi Yang

Richard Berger

Timothy A Blizzard

Zhengxia Chen

Brian T Campbell

Jiayi Xu

Sookhee Nicole Ha

Anilkumar G Nair

Meibi Dai

Libo Xu

Nelo R Rivera

Bart Harper

Zhiqiang Guo

Zhiyong Hu

Nam Fung Kar

Rui Zhang

Jason W Szewczyk

Dann Parker

Ming Wang

Jason Eugene Imbriglio

Ian Mangion

Pawan Dhondi

Zack Zhiqiang Guo

Mingxiang Cui

Jane Yang Wu

Jeffrey Donald Hermes

Michael Shevlin

Sunita V Dewnani

Byron Dubois

Reynalda De Jesus

Seongkon Kim

Rebecca T Ruck

Zaihong Zhang

Ying Lv

Lili Tian

Christopher J Mortko

Pawan K Dhondi

Helen Chen

Jason E Imbriglio

Jane Y Wu

Sookhee Ha

Nelo Rivera

Jeffrey D Hermes

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassium channel

Substituted bicyclic beta-lactams of Formula I: (I), are &#x3b2;-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with &#x3b2;-lactam antibiotics. In particular, the compounds can be employed with a &#x3b2;-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to &#x3b2;-lactam antibiotics due to the presence of the &#x3b2;-lactamases.

&#x3b2;-lactamase inhibitors

Growing community of inventors

Staten Island, NY, United States of America

Candido Gude